Vela Technologies (GB:VELA) has released an update.
Vela Technologies, an early-stage tech investment firm, has announced their stake in Conduit Pharmaceuticals Inc. following Conduit’s entry into an exclusive licensing agreement with AstraZeneca for pioneering treatments. Vela’s investment is currently valued at approximately $170,000, representing 0.46% of Conduit, which plans to initiate Phase II clinical trials for potential first-in-class treatments for autoimmune disorders and idiopathic male infertility.
For further insights into GB:VELA stock, check out TipRanks’ Stock Analysis page.
